Dxcover: Oncology Diagnostics Startup Selected for Drive Accelerator Program

SOUTH CAROLINA – April 1, 2026 – Dxcover is a clinical-stage diagnostics company developing AI-enabled liquid biopsy tests for early cancer detection. Its proprietary platform combines infrared spectroscopy with AI to analyze the full biochemical signature of blood, capturing both tumor and host-response signals. With one of the largest spectral multi-omic datasets globally and the first regulatory approval of its kind, Dxcover is scaling across the UK, EU, and US to deliver accessible, high-throughput cancer diagnostics.

Solutions

Dxcover has developed an AI-enabled liquid biopsy platform to improve early cancer detection by analyzing the full biochemical signature of blood. Its proprietary PANAROMIC™ platform combines infrared spectroscopy with machine learning to capture both tumor-derived and host-response signals, enabling detection where traditional molecular approaches are limited. Supported by one of the largest spectral multi-omic datasets globally and the first regulatory approval of its kind, the platform delivers rapid, low-cost, high-throughput testing within standard laboratory workflows. Dxcover is advancing applications across brain, gynecological and pancreatic cancers to enable earlier diagnosis and improved patient outcomes.

Strengths

  • Systemic Biology: Dxcover’s platform analyses the full biochemical signature of blood, capturing both tumor and host-response signals rather than relying solely on tumor-derived DNA.
  • Proven Dataset: Dxcover has generated one of the largest spectral multi-omic liquid biopsy datasets globally (~9,000+ patients and 250,000+ samples), underpinning model performance and ongoing product development.
  • Regulatory First: Dxcover has achieved the world’s first regulatory approval of a spectral multi-omic liquid biopsy, demonstrating clinical validity and readiness for deployment.
  • Scalable Platform: The PANAROMIC™ platform enables rapid, low-cost, high-throughput testing compatible with centralized laboratory workflows, supporting broad population-scale adoption.

Meet the Team

From left to right:

Matthew J. Baker, Ph.D., FRSC | Chief Executive Officer

Holly Butler, Ph.D. | Chief Technology Officer

David Palmer, Ph.D. | Chief Scientific Officer

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.